The first-in-human phase 1 trial of OP-3136, a novel orally bioavailable KAT6A/B inhibitor for solid tumors, started recruiting, with the prostate cancer cohort focusing on men with metastatic castration-resistant prostate cancer (mCRPC). This represents a significant expansion of OP-3136 beyond its initial focus on estrogen receptor-positive breast cancer, following encouraging preclinical data presented at AACR […]
The Alliance A222001 study, published in the Journal of Clinical Oncology in January 2026, found that oxybutynin, a drug typically used to treat overactive bladder, significantly reduces hot flashes in men receiving androgen-deprivation therapy (ADT), with improvements occurring within the first week of treatment and sustained throughout the study period. The findings could reshape how […]
The JASPER trial is a phase 1/2 study launching from the University of Michigan, takes a fundamentally different approach to castration-resistant prostate cancer by targeting the molecular machinery driving cancer plasticity from the start: the JAK/STAT inflammatory signaling axis. Understanding why this strategy makes biological sense requires stepping into what we now know about how […]
The ANDROMEDA phase 2 trial represents an advancement in managing recurrent oligometastatic prostate cancer by directly pitting alpha-emitting 225Ac-PSMA-617 against the established beta-emitting 177Lu-PSMA-617 (Pluvicto), both combined with stereotactic body radiotherapy (SBRT). This head-to-head comparison stems from the need to address limitations in current therapies for patients whose cancer returns in 1-5 detectable spots on […]
DCC-2812 is a new oral drug designed to fight advanced cancers, especially in the urinary and reproductive systems like kidney, bladder, and prostate cancers. It works by turning on a special stress response inside cancer cells that pushes them past their breaking point, leading to cell death. Cancer cells live in harsh environments with low […]
Preliminary results from an ongoing phase 1/2 trial combining docetaxel with the tumor-targeting IL-12 immunocytokine PDS01ADC (aka M9241) indicate promising early activity in patients with metastatic castration-resistant prostate cancer (mCRPC). The single-arm study, presented at the American Association for Cancer Research special conference on prostate cancer research, enrolled 16 patients with progressive mCRPC, most of […]
BNT324 (DB-1311) is rapidly emerging as one of the most promising new agents in metastatic castration-resistant prostate cancer (mCRPC), with a data package that is unusually strong for a first-in-class B7-H3–targeting antibody–drug conjugate and now compelling enough to justify a head‑to‑head Phase 3 trial against docetaxel. The reason it has attracted so much attention is […]
SKL35501 is an emerging radiopharmaceutical therapy that embodies much of what “next‑generation oncology” is supposed to mean: precise targeting, potent cell kill, and a built‑in companion diagnostic strategy. In January 2026, the US FDA cleared SKL35501 and its imaging partner SKL35502 for a phase 1 Investigational New Drug (IND). SKL35501 originated as FL‑091, a small‑molecule […]
ARREST trial could change mCRPC treatment by solving 177Lu-PSMA’s biggest limitation: up to 50% of patients get little benefit despite FDA approval and proven survival gains. The simple idea? Add targeted external beam radiation boosts to the tumors that radioligand therapy misses, creating a hybrid approach that could cut skeletal complications dramatically. Current 177Lu-PSMA therapy […]
Opevesostat, a first-in-class CYP11A1 inhibitor, blocks the first step of steroid hormone production, eliminating all ligands that activate mutant androgen receptors in metastatic castration-resistant prostate cancer (mCRPC). The Phase 3 MK-5684-004 aka OMAHA-004 trial tests it against standard next-generation hormonal agents (NHAs, like abiraterone, enzalutamide, …) switching in 1,500 patients progressed on one prior NHA, […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy